Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas

Autor: Francesco Merli, Luigi Rigacci, Umberto Vitolo, Andrea Ferrario, Barbara Olivero, Alessandra Tedeschi, Francesca Rossi, Maria Goldaniga, Giuseppe Rossi, Donato Mannina, Luca Baldini, Enrica Gamba, Alessandro Pulsoni, Caterina Stelitano, Pellegrino Musto

Publikováno v: Cancer. 118:3954-3961

BACKGROUND: Indolent nonfollicular non-Hodgkin B-cell lymphomas (INFLs) are clonal mature B-cell proliferations for which treatment has not been defined to date. METHODS: In this phase 2 study of patients with advanced INFL, the authors evaluated the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f3fa9e8c7d8a371b305b56ec382dda7
https://doi.org/10.1002/cncr.26708

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program

Autor: Ladetto, M., Lobetti-Bodoni, C., Mantoan, B., Ceccarelli, M., Boccomini, C., Genuardi, E., Chiappella, A., Baldini, L., Rossi, G., Pulsoni, A., Di Raimondo, F., Rigacci, L., Pinto, A., Galimberti, S., Bari, A., Rota-Scalabrini, D., Ferrari, A., Zaja, F., Gallamini, A., Specchia, G., Musto, P., Rossi, F. G., Gamba, E., Evangelista, A., Vitolo, U., Fondazione Italiana Linfomi: Chiara Lobetti-Bodoni, Barbara, Mantoan, Elisa, Genuardi, Mario, Boccadoro, Marco, Ladetto, Giovannino, Ciccone, Andrea, Evangelista, Manuela, Ceccarelli, Carola, Boccomini, Annalisa, Chiappella, Barbara, Botto, Lorella, Orsucci, Umberto, Vitolo, Maria, Goldaniga, Francesca Gaia Rossi, Luca, Baldini, Chiara, Bottelli, Alessandra, Tucci, Giuseppe, Rossi, Alessandro, Pulsoni, Federico De Angelis, Eleonora, Russo, Maurizio, Martelli, Robin, Foà, Francesco Di Raimondo, Annalisa, Chiarenza, Luigi, Rigacci, Benedetta, Puccini, Alberto, Bosi, Antonello, Pinto, Mario, Petrini, Sara, Galimberti, Alessia, Bari, Stefano, Sacchi, Massimo, Federico, Delia, Rota-Scalabrini, Massimo, Aglietta, Angela, Ferrari, Isabel Alvarez De Celis, Francesco, Merli, Francesco, Zaja, Renato, Fanin, Claudia, Castellino, Andrea, Gallamini, Guido, Parvis, Giuseppe, Saglio, Tommasina, Perrone, Giorgina, Specchia, Pellegrino, Musto, Enrica, Gamba, Paolo, Corradini, Enrico Maria Pogliani, Anna Marina Liberati, Giuseppe, Leone, Caterina, Patti, Giuseppe, Fioritoni, Chiara, Rusconi, Enrica, Morra, Anna, Tonso, Giuseppina, Cabras, Emanuele, Angelucci, Andrea, Rossi, Alessandro, Rambaldi, Sergio, Cortelazzo, Sergio, Morandi, Lanza, Francesco, Giovanni, Pizzolo, Sergio, Amadori, Pier Luigi Zinzani, Caterina, Stelitano, Francesco, Nobile

We assessed the prognostic value of minimal residual disease (MRD) within the ML17638 phase 3 trial from the Fondazione Italiana Linfomi, investigating the role of rituximab maintenance in elderly follicular lymphoma (FL) patients after a brief first

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4d9b1413ed2928320b066d5df92efb6
https://hdl.handle.net/11380/1148609

A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: Results of the induction phase

Autor: Maura Brugiatelli, Francesco Forconi, F.R. Mauro, Agostino Cortellezzi, Stefania Ciolli, Massimo Massaia, Alessandra Alietti, Antonio Cuneo, Rita Rizzi, Livio Trentin, Francesco Nobile, Enrica Gamba, Robert Foa, Lorella Orsucci, Maria Angela Mura, Eva J. Runggaldier, Stefano Molica, Anna Guarini, F. Di Raimondo, G Del Poeta

6629 Background: The FCR regimen (fludarabine, cyclophosphamide, rituximab) significantly improves the outcome of patients (pts) with chronic lymphocytic leukemia (CLL). However, myelotoxicity and immunosuppression are a limitation to the use of this

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11ec92aaa42bf17b0d487fb63af8eb81
http://hdl.handle.net/11573/500977

Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia

Autor: Renato Fanin, Rita Rizzi, Michele Baccarani, Patrizio Mazza, Emanuele Angelucci, Selenia Campagna, Silvia Cantoni, Enrica Gamba, Valerio De Stefano, Felicetto Ferrara, Giuseppe Visani, Marzia Defina, Franca Soldano, Sergio Amadori, Emilio Usala, Alfonso Zaccaria, Francesco Casulli, Alessia Tieghi, Antonella Fornaro, Miriam Isola, Luigi Gugliotta, Monica Bocchia, Marta Lisa Battista, Francesco Zaja, Nicola Vianelli

Previous observational studies suggest that rituximab may be useful in the treatment of primary immune thrombocytopenia (ITP). This randomized trial investigated rituximab efficacy in previously untreated adult ITP patients with a platelet count of 2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::075770f87340e838aa95173f0f9da42d
http://hdl.handle.net/11365/10970

Rituximab (R) Maintenance Versus Observation After Short Term Chemo-immunotherapy R-FND as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Updated Results and Safety of the Maintenance of An Intergruppo Italiano Linfomi (IIL) Randomized Trial

Autor: Samantha Pozzi, Antonello Pinto, Andrea Gallamini, Annalisa Chiarenza, Attilio Guarini, Corrado Tarella, Luca Baldini, Eleonora Russo, Alessandra Tucci, Paolo Corradini, Mario Petrini, Eugenio Gallo, Lorella Orsucci, Guido Parvis, Barbara Mantoan, Amalia De Renzo, Francesco Zaja, Anna Marina Liberati, Enrica Gamba, Stefan Hohaus, Umberto Vitolo, Enrico Pogliani, Luigi Rigacci, Annalisa Chiappella, Alessandro Pulsoni, Andrea Evangelista, Isabel Alvarez, Carola Boccomini, Marco Ladetto

Publikováno v: Web of Science

Abstract 1706 Poster Board I-732 Introduction in order to maintain efficacy and reduce toxicity of the treatment in elderly follicular lymphoma (FL) patients, we designed a study with a short chemo-immunotherapy R-FND with Rituximab consolidation fol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62231e968fe484f84744d16de0f3f107
http://hdl.handle.net/11391/1011119